GlassScriptPhysician profile
Delma Jara
NPI 1407822562
$728.36
in general payments reported to CMS, 2019-2025
15 companies · $106 in 2025
The $106 reported for 2025 was less than what a typical Surgery provider received nationally (typical 2025 total: $281).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $15.51 · 2020: $4.24 · 2021: $65.66 · 2022: $213 · 2023: $136 · 2024: $188 · 2025: $106.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $430.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $429.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organogenesis INC. | $369.69 | 2022-2025 | Puraply Wound Matrix, Puraply, Apligraf |
| Hydrofera LLC | $65.04 | 2021-2023 | Hydrofera Blue |
| Medela LLC | $52.56 | 2022 | |
| Advanced Oxygen Therapy INC. | $35.13 | 2024 | Topical Oxygen Chamber For Extremities |
| Smith+Nephew, INC. | $31.18 | 2021-2022 | |
| Ets Wound Care LLC | $28.89 | 2024 | Mirragen Advanced Wound Matrix |
| Omeza LLC | $26.79 | 2023 | |
| Kerecis Limited | $20.37 | 2021 | |
| Next Science LLC | $17.59 | 2021 | |
| Kci USA, INC. | $16.56 | 2023 | Activ.A.C. Ion Progress, V.A.C. Dermatac, V.A.C. Veraflo |
| Ovik Health, LLC | $16.39 | 2023 | |
| Convatec INC. | $15.51 | 2019 | |
| Integra Lifesciences Corporation | $14.77 | 2022 | |
| Acera Surgical, INC. | $13.65 | 2024 | Restrata Wound Matrix |
| Aroa Biosurgery Incorporated | $4.24 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Delma Jara listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.